Log in
Donate
Search
Close this search box.

Clinical Trial: ECOG-ACRIN EA5181

ECOG-ACRIN EA5181

Status: Closed

NCT#04092283

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

EA5181 is closed to accrual, effective November 20, 2013.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved